このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

The Restorative Role of Daytime Naps in Mentally Fatigued Endurance Athletes (Nap&Run)

2026年5月5日 更新者:Jacopo Vitale、L.U.de.S. Sagl

The Restorative Role of Daytime Naps in Mentally Fatigued Endurance Athletes: a Randomized Controlled Trial

This randomized, counterbalanced crossover study investigated whether a 30-minute daytime nap can mitigate the effects of experimentally induced mental fatigue in amateur master endurance athletes. Male athletes completed two home-based experimental sessions separated by one week: a mental fatigue condition, in which a 30-minute cognitively demanding task battery preceded the nap, and a control condition, in which participants took only the nap. Sleep parameters during the nap were monitored by wrist actigraphy, and perceived sleep quality was assessed after awakening. Subjective sleepiness, perceived mental fatigue, and cognitive performance were evaluated before the nap, immediately after the nap, and/or 30 minutes after the nap.

The study examined whether mental fatigue influenced nap characteristics and whether the nap improved recovery-related outcomes. The main outcomes included actigraphy-derived nap parameters, perceived sleep quality, sleepiness assessed with the Karolinska Sleepiness Scale, perceived mental fatigue assessed using a visual analogue scale, and cognitive performance assessed with a Flanker task.

調査の概要

研究の種類

介入

入学 (実際)

11

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Male amateur master endurance athletes
  • Age between 28 and 50 years
  • Peak oxygen uptake (VO₂peak) ≥55 mL·kg-¹·min-¹
  • Habitual nocturnal sleep duration of at least 7 hours
  • Able and willing to complete both experimental sessions and daytime nap procedures

Exclusion Criteria:

  • Diagnosed medical condition or injury
  • Diagnosed sleep disorder
  • Use of medications or supplements affecting sleep or cognition, including melatonin
  • Habitual sleep duration of less than 7 hours per night
  • Inability to nap during the experimental sessions

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Mental Fatigue + Daytime Nap
Participants completed a 30-minute mental fatigue induction protocol consisting of cognitively demanding tasks, followed by a 30-minute daytime nap performed at home between 14:00 and 15:00. Subjective sleepiness, perceived mental fatigue, nap characteristics, perceived sleep quality, and cognitive performance were assessed before and/or after the nap.
Participants completed a 30-minute computerized cognitive task battery designed to induce mental fatigue before the daytime nap. The protocol consisted of three consecutive 10-minute cognitively demanding tasks: a Flanker task, a memory task, and a Stroop task.
Participants took a 30-minute daytime nap at home between 14:00 and 15:00, at least one hour after lunch, in a quiet and dimly lit room. Nap characteristics were monitored using wrist actigraphy, and perceived sleep quality was assessed after awakening.
アクティブコンパレータ:Daytime Nap Control
Participants completed the control condition consisting of a 30-minute daytime nap performed at home between 14:00 and 15:00, without the preceding mental fatigue induction protocol. Subjective sleepiness, perceived mental fatigue, nap characteristics, perceived sleep quality, and cognitive performance were assessed before and/or after the nap.
Participants took a 30-minute daytime nap at home between 14:00 and 15:00, at least one hour after lunch, in a quiet and dimly lit room. Nap characteristics were monitored using wrist actigraphy, and perceived sleep quality was assessed after awakening.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Perceived mental fatigue
時間枠:Before the nap, immediately after the nap, and 30 minutes after the nap in each experimental condition.
Perceived mental fatigue was assessed using a 100-mm visual analogue scale for mental fatigue (VAS-MF), anchored from 0-mm "No mental fatigue" to 100-mm "Maximum mental fatigue." Participants marked the point that best represented their perceived level of mental fatigue.
Before the nap, immediately after the nap, and 30 minutes after the nap in each experimental condition.

二次結果の測定

結果測定
メジャーの説明
時間枠
Subjective sleepiness
時間枠:Before the nap, immediately after the nap, and 30 minutes after the nap
Subjective sleepiness was assessed using the Karolinska Sleepiness Scale (KSS), a 9-point scale ranging from 1, "not sleepy at all," to 9, "extremely sleepy."
Before the nap, immediately after the nap, and 30 minutes after the nap
Flanker Task Reaction Time
時間枠:30 minutes after the nap in each experimental condition.
Accuracy during the computerized Flanker task was calculated as the percentage of correct responses and used as an indicator of executive function performance. Accuracy ranges from 0 to 100%.
30 minutes after the nap in each experimental condition.
Perceived Nap Sleep Quality
時間枠:Immediately after the nap in each experimental condition.
Perceived sleep quality after the nap was assessed using a 10-point Likert scale, from 0 to 10, with higher scores indicating better perceived sleep quality.
Immediately after the nap in each experimental condition.
Actigraphy-Derived nap start time
時間枠:During the 30-minute daytime nap in each experimental condition.
Clock time at which the nap period begins, usually identified from the rest interval or sleep diary. Nap start time is expressed as clock time, using the 24-hour format.
During the 30-minute daytime nap in each experimental condition.
Actigraphy-Derived nap time in bed
時間枠:During the 30-minute daytime nap in each experimental condition.
Total time spent in bed or within the defined nap/rest interval, from nap start time to nap end time. Values are expressed in minutes.
During the 30-minute daytime nap in each experimental condition.
Actigraphy-Derived nap total sleep time
時間枠:During the 30-minute daytime nap in each experimental condition.
Total duration of epochs scored as sleep during the nap/rest interval. Values are expressed in minutes.
During the 30-minute daytime nap in each experimental condition.
Actigraphy-Derived nap sleep onset latency
時間枠:During the 30-minute daytime nap in each experimental condition.
Time elapsed between nap start time and the first epoch scored as sleep. Values are expressed in minutes.
During the 30-minute daytime nap in each experimental condition.
Actigraphy-Derived nap sleep efficiency
時間枠:During the 30-minute daytime nap in each experimental condition.
Sleep efficiency is expressed as a percentage, ranging from 0% to 100%, and is calculated as the ratio between total sleep time and time in bed multiplied by 100
During the 30-minute daytime nap in each experimental condition.
Actigraphy-Derived nap fragmentation index
時間枠:During the 30-minute daytime nap in each experimental condition.
An index reflecting sleep disruption or restlessness, based on movement and short immobility bouts during the sleep period. Higher values indicate more fragmented sleep. Fragmentation index is expressed as a percentage from 0% to 100%
During the 30-minute daytime nap in each experimental condition.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年1月11日

一次修了 (実際)

2021年5月15日

研究の完了 (実際)

2021年5月15日

試験登録日

最初に提出

2026年4月28日

QC基準を満たした最初の提出物

2026年5月5日

最初の投稿 (実際)

2026年5月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月12日

QC基準を満たした最後の更新が送信されました

2026年5月5日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be made publicly available. Data supporting the findings of this study may be available from the corresponding author upon reasonable request.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する